uniQure N.V.
General ticker "QURE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
uniQure N.V. follows the US Stock Market performance with the rate: 22.6%.
Estimated limits based on current volatility of 1.4%: low 21.27$, high 22.29$
Factors to consider:
- Total employees count: 221 (+5.7%) as of 2025
- Top business risk factors: Product development failure, Economic downturns and volatility, Regulatory and compliance, Manufacturing scale up, Capital constraints
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [12.37$, 29.65$]
- 2026-12-31 to 2027-12-31 estimated range: [8.14$, 21.02$]
Financial Metrics affecting the QURE estimates:
- Negative: with PPE of -7.1 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -22.84 <= -18.95
Short-term QURE quotes
Long-term QURE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15.84MM | $27.12MM | $16.10MM |
| Operating Expenses | $298.71MM | $211.41MM | $203.93MM |
| Operating Income | $-282.87MM | $-184.29MM | $-187.83MM |
| Non-Operating Income | $-23.69MM | $-52.83MM | $-5.51MM |
| Interest Expense | $41.56MM | $63.74MM | $61.99MM |
| R&D Expense | $214.86MM | $143.78MM | $140.67MM |
| Income(Loss) | $-306.56MM | $-237.13MM | $-193.34MM |
| Taxes | $1.92MM | $2.43MM | $5.63MM |
| Net Income(Loss)* | $-308.48MM | $-239.56MM | $-198.97MM |
| Stockholders Equity | $207.67MM | $-6.75MM | $198.90MM |
| Inventory | $12.02MM | $0.00MM | $0.00MM |
| Assets | $831.69MM | $556.54MM | $824.91MM |
| Operating Cash Flow | $-145.93MM | $-182.73MM | $-177.96MM |
| Capital expenditure | $7.15MM | $3.37MM | $0.44MM |
| Investing Cash Flow | $-205.69MM | $162.97MM | $-321.62MM |
| Financing Cash Flow | $362.72MM | $-59.49MM | $415.40MM |
| Earnings Per Share** | $-6.47 | $-4.92 | $-3.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.